FDA Drug Shortage: Desmopressin Acetate Spray (Current)

FDA reports an ongoing shortage of desmopressin acetate nasal spray, a critical medication for treating central diabetes insipidus and primary nocturnal enuresis. The shortage stems from manufacturing quality issues — specifically, the manufacturer's inability to meet current good manufacturing practice (cGMP) requirements under 21 CFR Part 211.

Regulatory Background

Under the FDA Safety and Innovation Act (FDASIA) of 2012, manufacturers must notify FDA of permanent discontinuances or interruptions in manufacturing that are likely to lead to a drug shortage. When a shortage is caused by quality or manufacturing issues, FDA publicly reports the reason and works with manufacturers to resolve deficiencies.

Current good manufacturing practices are mandatory quality standards established under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. Non-compliance with cGMP can result in enforcement action, including facility inspections, warning letters, consent decrees, and production holds. In shortage situations, FDA typically works with the manufacturer to remediate violations rather than immediately pursuing enforcement — but this depends on the severity of the deficiency.

Key Details

Product: Desmopressin Acetate Nasal Spray, 0.01% (10 mcg/spray), 5 mL bottle

Manufacturer: Ferring Pharmaceuticals Inc.

Shortage reason: Requirements related to complying with good manufacturing practices

Current status: Ongoing shortage

Alternative products: FDA has not authorized temporary importation of foreign-approved desmopressin products. Clinicians may consider switching patients to desmopressin tablets (oral formulation) where clinically appropriate, though bioavailability differs significantly between intranasal and oral routes.

FDA's drug shortage database does not specify which cGMP requirements Ferring failed to meet, nor does it disclose whether FDA issued a Form 483 observation, warning letter, or consent decree. This is standard — FDA generally does not publish enforcement details until action is finalized.

Wholesale distributors should note: desmopressin is not a controlled substance and does not require DEA registration, but it is a prescription-only drug subject to the Drug Supply Chain Security Act's transaction documentation and product tracing requirements.

Impact on Wholesale Drug Distributors

Shortages driven by cGMP violations create distinct risks for the distribution chain:

Counterfeit and diversion risk increases. When legitimate supply contracts, gray-market suppliers surface. Wholesale distributors receiving offers for desmopressin acetate spray from unfamiliar sources must verify the seller's state licensure and DSCSA compliance. Under 21 USC 360eee-1(a)(2), distributors may only conduct transactions with "authorized trading partners" — entities properly licensed under state law.

Transaction documentation becomes more critical. During shortages, product may change hands multiple times before reaching the dispenser. Each wholesale distributor in the chain must provide transaction history, transaction information, and transaction statement (the "3T" documentation) as required under DSCSA. Missing or incomplete 3Ts disqualify a transaction.

Cold chain integrity is not directly affected — desmopressin acetate spray is stored at controlled room temperature (20-25°C), not refrigerated. However, distributors handling therapeutic alternatives (such as injectable desmopressin, which requires refrigeration) must ensure cold chain-qualified storage and transportation.

State boards may increase scrutiny. Some state pharmacy boards issue alerts during drug shortages reminding distributors of their obligation to report suspected counterfeits. Distributors should review their state's specific requirements for reporting suspicious offers or illegitimate products.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these, 1,234 hold active FDA establishment registrations — a baseline requirement for entities handling prescription drugs like desmopressin acetate spray. However, FDA registration alone does not guarantee cGMP compliance. Manufacturing facilities face regular FDA inspections; wholesale distributors are subject to state pharmacy board inspections that verify storage conditions and handling procedures.

The average compliance score in ColdChainCheck's directory is 51/100, placing most entities in the "Fair" tier. Only 63 entities hold NABP accreditation (formerly VAWD), which requires passing a comprehensive audit of facility operations, quality systems, and state licensure status. During drug shortages, the gap between baseline-compliant entities (FDA-registered, state-licensed) and verified-compliant entities (NABP-accredited, clean enforcement history) becomes operationally significant.

73 entities in the directory have at least one FDA recall on record. While not all recalls indicate systemic quality issues — some result from labeling errors or isolated batch problems — a pattern of recalls may signal cGMP deficiencies similar to those causing the desmopressin shortage.

Practical Guidance for QA and Procurement Teams

Verify trading partners before accepting desmopressin offers. Use the ColdChainCheck directory to confirm that any distributor offering shortage products holds active state licenses and FDA registration. Entities with compliance scores below 40 (the "Poor" tier) require additional due diligence.

Cross-reference NABP accreditation status. Only 63 entities in our database are NABP-accredited. If a potential supplier claims accreditation, verify against ColdChainCheck's data or NABP's public list. Accredited distributors undergo annual facility audits and are less likely to handle diverted or counterfeit product.

Check enforcement history. Entities with recent FDA recalls or state board disciplinary actions carry elevated risk during shortages. ColdChainCheck's entity profiles include publicly reported recalls and enforcement actions sourced from FDA and state boards.

Document your vendor qualification process. During audits, inspectors will ask how you verified trading partner legitimacy during a shortage. ColdChainCheck's compliance scores and license verification data provide auditable documentation of your due diligence process.

For ongoing coverage of FDA drug shortages and wholesale distributor compliance, see ColdChainCheck's regulatory guides.

Disclaimer: This article provides informational content based on publicly available FDA data and regulatory requirements. It is not legal or compliance advice. Entities should consult qualified legal counsel and verify all regulatory requirements with the relevant authorities.